į.

Signature

A

Please type a plus sign (+) inside this box → +

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION

Attorney Docket No. 1000.06.003

First Inventor AGATA, ET AL.

Title Tumor Chemopotentiation Using Isocoumarin Derivatives

TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No.

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Expres	s Mail Label No. ET163419644US
	0 ==
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO:  Assistant Commissioner for Palents Box Patent Application Washington, D.C. 20231
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table of Computer Program (Appendix)
2. Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submisson (if applicable, all necessary)
3. Specification [Total Pages 48]	a. Computer Readable Form (CRF)
- Descriptive title of the invention	bSpecification_Sequence Listing on:
<ul> <li>Cross Reference to Related Applications</li> </ul>	<ul> <li>i. CD-ROM or CD-R (2 copies); or</li> </ul>
<ul> <li>Statement Regarding Fed sponsored R &amp; D</li> <li>Reference to sequence listing, a table,</li> </ul>	ii. paper
or a computer program listing appendix	
- Background of the Invention	c. Statements verifying identity of above copies
<ul> <li>Brief Summary of the Invention</li> <li>Brief Description of the Drawings (if filed)</li> </ul>	ACCOMPANYING APPLICATION PARTS
- Detailed Description	Assignment Papers (cover sheet & document(s))
- Claim(s) - Abstract of the Disclosure	10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney
	11. English Translation Document (if applicable)
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 14]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
5. Oath or Declaration [Total Pages 6]	13. Preliminary Amendment
a. Newly executed (original or copy)	Return Receipt Postcard (MPEP 503)
Copy from a prior application (37 CFR 1.63(c	(Should be specifically itemized)
b. (for continuation/divisional with Box 18 completed)	15. Certified Copy of Priority Document(s) (If foreign priority is claimed)
i. <u>DELETION OF INVENTOR(S)</u>	Nonpublication Request under 35 U.S.C. 122
Signed statement attached deleting invento named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	(s) (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
6. Application Data Sheet. See 37 CFR 1.76	17. Other:
	d supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76:	зарру ше теризне иногналоп веюм ана ига ргенингагу апенинела,
Continuation Divisional Continuation-in-	art (CIP) of prior application No.: 09/794,417
Prior application information: Examiner Jerome D. Goldb	erg Group / Art Unit: 1614
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the accompanies of the disclosure of the accompanies of the disclosure of the accompanies.	ure of the prior application, from which an oath or declaration is supplied anying continuation or divisional application and is hereby incorporated by
reference. The incorporation can only be relied upon when a portion	has been inadvertently omitted from the submitted application parts.
19. CORRESP	ONDENCE ADDRESS
	or Correspondence address below
. 31	7/6
Name PATENT TRAD	EMAPK OFFICE
Address	
City State	Zip Code
Country Telephone	. Fax
Name (Print/Type) STEPHEN J. MOKONEY M	Registration No. (Attorney/Agent) 44,947

Burden Hour Statement: This form is estimated to take 0.2 bords to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SENID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Flox Patent Application, Washington, DC 20231.

Date

SUBMITTED BY

Name (Print/Type

Signature

Complete (if applicable)

210 949 8273

Telephone

Date

PTO/SB/17 (11-01)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to espond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL			Complete if Known				
FEE TRANSMITTAL for FY 2002		App	lication	Numb	oer		
10r F ¥ 2002		Filin	g Date	1		02/22/02	
Patent fees are subject to annual revision.		First	Name	d Inve	ntor	AGATA, ET AL.	
Applicant claims small entity status. See 37 CFR 1.27		Exa	miner I	Vame			•
		Gro	up Art	Unit			
TOTAL AMOUNT OF PAYMENT \$412		Atto	rney D	ocket	No.	1000.06.003	
METHOD OF PAYMENT (check all that apply)				FE	E C	ALCULATION (continued)	
Check Credit card Money Other None		ADDITI					
Deposit Account:	Fee	Entity Fee	Smal	Fee	<u>-</u>	Fee Description	Fee Paid
Deposit Account 501786	Code 10		Code 205	( <b>\$</b> ) 65	Surch	harge - late filing fee or oath	- Tec Paid
Number	12					harge - late provisional filing fee or cover	
Deposit					sheet	<u>t</u>	
Name	13	9 130 7 2,520				- English specification iling a request for ex parte reexamination	
The Commissioner is authorized to: (check all that apply)	11	•	I	920*		uesting publication of SIR prior to Examiner	
Charge fee(s) indicated below Credit any overpayments  Charge any additional fee(s) during the pendency of this application	ı				action	n ·	
Charge fee(s) indicated below, except for the filing fee	11	3 1,840*	113	1,840*	Requ	uesting publication of SIR after Examiner on	
to the above identified deposit account.	11	5 110	215	55	Exter	nsion for reply within first month	
FEE CALCULATION	11	6 400	216	200	Exter	nsion for reply within second month	
1. BASIC FILING FEE	11	7 920	217	460	Exter	nsion for reply within third month	
Large Entity   Small Entity	11	8 1,440	218	720	Exter	nsion for reply within fourth month	
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	12	8 1,960	228	980		nsion for reply within fifth month	
101 740 201 370 Utility filing fee 370.00	] 11			160		ce of Appeal	
106 330 206 165 Design filing fee	] 12			160	_	g a brief in support of an appeal	
107 510 207 255 Plant filing fee	] 12			140		uest for oral hearing	
108 740 208 370 Reissue filing fee	' I	8 1,510				ion to institute a public use proceeding	
114 160 214 80 Provisional filing fee	14			55		ion to revive - unavoidable	
SUBTOTAL (1) \$370.00	J∎	1 1,280		640		ion to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND		2 1,280		640		y issue fee (or reissue)	
Fee from Extra Claims below Fee Pal	14		1	230	_	gn issue fee	
Total Claims 20 -20** = 0 X = 0.00	ו וי	-		310		t issue fee ions to the Commissioner	
Independent 4 - 3** = 1 X 42.00 = 42.00	12			130 50		essing fee under 37 CFR § 1.17(q)	
Multiple Dependent =	] 12			180		mission of Information Disclosure	
Large Entity   Small Entity					State	ement	
Fee Fee Fee Fee Description Code (\$)	58	11 40	581		(time:	ording each patent assignment per property es number of properties)	
103 18 203 9 Claims in excess of 20	14	6 740	246	370		g a submission after final rejection CFR § 1.129(a))	
102 84 202 42 Independent claims in excess of 3		9 740	249	370	For e	each additional invention to be examined	
104 280 204 140 Multiple dependent claim, if not paid 1 109 84 209 42 ** Reissue independent claims		9 740	279	370	•	CFR § 1.129(b))  Lest for Continued Examination (RCE)	
over original patent	16		ł		Requ	uest for expedited examination	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent		of a design application  Other fee (specify)					
SUBTOTAL (2) \$42.00	7						
**or number previously paid, if greater; For Reissues, see above	-B	educed I	by Basic	Filina	Fee P	Paid SUBTOTAL (3)	

WARNING: Information on this form may bec m public. Credit card inf rmati n sh uld n t b includ d on this f rm. Provid cr dit card inf rmati n and auth rizati n n

STEPHEN L'MOLONE

Registration No. (Attorney/Agent)

44947



St phen J. M I ney, Ph.D., J.D.
Associate Counsel
Intellectual Property

(210) 949-8273 phone (210) 949-8261 fax smoloney@ilexonc.com

February 22, 2002

VIA EXPRESS MAIL # ET163419644US

Patent Application for: TUMOR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES Inventors: Agata & Kharbanda

Dear Sir:

Enclosed please find the following in the above-referenced matter:

- 1. Utility Patent Application Transmittal Sheet;
- 2. Fee Transmittal for FY 2002 plus 1 copy;
- 3. Utility Patent Application;
- 4. 14 sheets of drawings; and
- 5. Return receipt postcard.

Commissioner is hereby authorized to charge the filing fee for the above referenced application, in the amount of \$412.00, to Deposit Account No. 501786. Further, under 37 CFR §§ 1.16 and 1.17, Commissioner is authorized to charge any deficiency in fees in this matter to the same deposit account. Please associate this file with Customer No. 31076.

Respectfully submitted

Stephen J. Moloney Reg. No. 44,947

plicant(s): AGATA, E	MAILI BY "EXPRESS M TAL.	MAIL" (37 CFR 1.16,	Docket No. 1000.06.003
Serial No.	Filing Date 02/22/02	Examiner	Group Art Unit
vention: TUMOR CHI	EMOPOTENTIATION USING IS	SOCOUMARIN DERIVATIVE	S
I hereby certify that the	following correspondence:		
FEE T	RANSMITTAL	FY 2002	+ 1 COPY
	(Identify type o	f correspondence)	
is being deposited with	the United States Postal Service	ce "Express Mail Post Office to	Addressee" service unde
•			
37 CFR 1.10 in an enve	elope addressed to: The Assista	nt Commissioner for Patents, V	Washington, D.C. 20231 of
02/22/	02		
(Date)		•	
(Date)		HRANCES WIT	
(Date)		HRANCES WIN	
(Date)		(Typed or Printed Name of Person M	failing Correspondence)
(Date)			failing Correspondence)
(Date)		(Typed or Printed Name of Person M	Correspondence)
(Date)		(Typed or Printed Name of Person M (Signature of Person Mailing	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person M (Signature of Person Mailing ET16341964	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person M (Signature of Person Mailing ET16341964	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person M (Signature of Person Mailing ET16341964	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person Mailing (Signature of Person Mailing ET16341964 ("Express Mail" Mailing I	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person M (Signature of Person Mailing ET16341964	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person Mailing (Signature of Person Mailing ET16341964 ("Express Mail" Mailing I	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person Mailing (Signature of Person Mailing ET16341964 ("Express Mail" Mailing I	failing Correspondence)  Correspondence)  4US
(Date)		(Typed or Printed Name of Person Mailing (Signature of Person Mailing ET16341964 ("Express Mail" Mailing I	failing Correspondence)  Correspondence)  4US

02/22/02	RTIFICATE OF M		S MAIL" (37 CFR 1.1	Docket No. 1000.06.003
hereby certify that the following correspondence:  UTILITY PATENT Application CIP  (Identify type of correspondence)  being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 or 02/22/02  (Date)  RANCES WINKLER  (Typed or Printed National Correspondence)  (Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	Serial No.		Examiner	Group Art Unit
DTILITY PATENT APPLICATION CIP  (Identify type of correspondence)  being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of 02/22/02  (Date)  (Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	ention: TUMOR CHE	MOPOTENTIATION USING	G ISOCOUMARIN DERIVATIVE	s
being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of 02/22/02 (Date)  FRANCES WINKLER  (Typed or Printed Tanks of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	hereby certify that the t	following correspondence:		
being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of 02/22/02  (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	UTILITY	PATENT AP	PLICATION CI	P 
7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 o  02/22/02 (Date)  FRANCES WINKLER (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  ET163419644US ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.		(Identify ty	pe of correspondence)	
7 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 o  02/22/02 (Date)  FRANCES WINKLER (Typed or Printed Value) of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  ET163419644US ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	being deposited with	the United States Postal Se	rvice "Express Mail Post Office to	Addressee" service unde
(Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	being deposited min	the office offices i ocial oc	THOSE Express man room of more	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
(Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.				
(Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	7 CFR 1.10 in an enve	lope addressed to: The Assis	stant Commissioner for Patents, V	Washington, D.C. 20231 or
(Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.			stant Commissioner for Patents, V	Vashington, D.C. 20231 or
(Signature of Person Mailing Correspondence)  ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	02/22/0		stant Commissioner for Patents, V	Vashington, D.C. 20231 or
ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	02/22/0		۸	
ET163419644US  ("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	02/22/0		FRANCES WIT	NKLER
("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	02/22/0		FRANCES WIT	NKLER
("Express Mail" Mailing Label Number)  Note: Each paper must have its own certificate of mailing.	02/22/0		FRANCES WIN (Typed or Printed Name of Person M	NKLER Tailing Correspondence)
Note: Each paper must have its own certificate of mailing.	02/22/0		FRANCES WIN (Typed or Printed Name of Person M (Signature of Person Mailing	NKLER (ailing Correspondence) Correspondence)
	02/22/0		FRANCES WIN  (Typed or Printed Name of Person M  (Signature of Person Mailing  ET16341964	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		FRANCES WIN  (Typed or Printed Name of Person M  (Signature of Person Mailing  ET16341964	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		FRANCES WIN  (Typed or Printed Name of Person M  (Signature of Person Mailing  ET16341964	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		FRANCES WIN  (Typed or Printed Name of Person M  (Signature of Person Mailing  ET16341964	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		FRANCES WIN  (Typed or Printed Name of Person M  (Signature of Person Mailing  ET16341964	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		(Typed or Printed Name of Person Mailing  (Signature of Person Mailing  ET16341964  ("Express Mail" Mailing I	NKLER Tailing Correspondence)  Correspondence)  4US
	02/22/0		(Typed or Printed Name of Person Mailing  (Signature of Person Mailing  ET16341964  ("Express Mail" Mailing I	NKLER [ailing Correspondence)  Correspondence)  4US [abel Number]
	02/22/0		(Typed or Printed Name of Person Mailing  (Signature of Person Mailing  ET16341964  ("Express Mail" Mailing I	NKLER [ailing Correspondence)  Correspondence)  4US [abel Number]

cant(s): AGATA, E	<del>-</del>	ESS MAIL" (37 CFR 1.16,	Docket No. 1000.06.003
Serial No.	Filing Date 02/22/02	Examiner	Group Art Unit
ntion: TUMOR CHI	EMOPOTENTIATION US	SING ISOCOUMARIN DERIVATIV	ES
	following correspondence		
14 Pag	ges of Inf	formal Drawing	S
	- <i></i>	ify type of correspondence)	
02/22/ (Date)	02	Assistant Commissioner for Patents,	
		(Typed or Printed Nume of Person (Signature of Person Mailin	
·		ET163419	644US
		("Express Mail" Mailing	